Thursday, 23 November 2017 08:24

Influenza vaccine and susceptibility - MTM 70

Stacey Schultz-Cherry explains the selection process to choose the influenza virus strains to include in the annual influenza vaccine.

Tuesday, 05 September 2017 19:52

The Red Queen meets the White Rabbit - TWiV 457

The distribution of proteins on the influenza viral genome, and the evolution of myxoma virus that was released in Australia to control the rabbit population.

Published in TWiV
Monday, 19 June 2017 08:35

Old sins die hard - TWiV 446

The TWiV hosts review an analysis of gender parity trends at virology conferences, and the origin and unusual pathogenesis of the 1918 pandemic H1N1 influenza virus.

Published in TWiV

TWiV reveals the cost of being a male mouse – the Y chromosome regulates their susceptibility to influenza virus infection.

Published in TWiV

At Cornell University in Ithaca, New York, Vincent speaks with Susan, Colin, and Gary about the work of their laboratories on parvoviruses, influenza viruses, and coronaviruses that infect dogs, cats, horses and other mammals.

Published in TWiV

Going somewhere exotic? Travel vaccinations are more than just a prick in the arm. Learn what pesky pathogens you’re protecting yourself from next time you trot the globe

Published in Microbial Sciences
Tuesday, 24 January 2017 08:57

Influenza Viruses by James McSharry, PhD

In this ASM Virtual Lecture Dr. James McSharry, Professor Emeritus, Albany Medical College, describes the structure of the influenza viruses,  types of human influenza viruses and their replication in cells,  licensed influenza drugs, current influenza vaccines, and the future of influenza vaccines.

Published in ASM Virtual Lectures
Friday, 09 December 2016 15:02

I "Flu" in for the Holidays

Each year, millions across the globe travel for the holidays. But with the increase in human travel, what microbial gifts are we bringing home with us?

Published in Microbial Sciences
Thursday, 12 September 2013 16:05

High Dose Therapy for Influenza Drug ICAAC 2013

Critically ill patients with the pandemic H1N1 influenza who received triple the standard dose of the influenza drug oseltamivir were 7 times more likely to completely clear the virus from their system in 5 days than those who received the standard dose. This discussion addresses the healthcare implications of these findings, including a rationale for high dose therapy of sensitive strains of influenza.

Published in ICAAC in Denver 2013

Public health officials provide the latest update on the H3N2, the new strain of influenza that appears to have jumped from swine to humans and has already infected nearly 300 people in the United States.

Page 1 of 2

TPL_asm2013_ADDITIONAL_INFORMATION

TPL_asm2013_SEARCH